Metagenomi Therapeutics (MGX) Share-based Compensation (2023 - 2026)

Metagenomi Therapeutics (MGX) has 4 years of Share-based Compensation data on file, last reported at $2.6 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $2.6 million, down 12.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.5 million (down 18.46% YoY), and the FY2025 annual result was $11.9 million, down 26.85% from the prior year.
• Share-based Compensation eased to $2.6 million in Q1 2026 per MGX's latest filing, from $2.7 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $5.1 million in Q1 2024 and troughed at $529000.0 in Q1 2023.
• A 4-year average of $2.9 million and a median of $3.0 million in 2025 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation soared 855.95% in 2024, then sank 42.1% in 2025.
• A 4-year view of Share-based Compensation shows it stood at $2.5 million in 2023, then jumped by 38.19% to $3.4 million in 2024, then decreased by 21.04% to $2.7 million in 2025, then declined by 5.27% to $2.6 million in 2026.
• Business Quant data shows MGX's Share-based Compensation at $2.6 million in Q1 2026, $2.7 million in Q4 2025, and $3.0 million in Q3 2025.